Two-Drug Combo Promising for HIV Remission

Share this content:
Two-Drug Combo Promising for HIV Remission
Two-Drug Combo Promising for HIV Remission

FRIDAY, Nov. 11, 2016 (HealthDay News) -- Animal research with an experimental two-drug therapy could hold clues for creating long-term HIV remission, according to a report published online Nov. 9 in Nature.

The two-year study involved 36 monkeys infected with simian immunodeficiency virus (SIV). The monkeys initially were treated with antiretroviral drugs for six months. Then they were treated with different combinations of experimental vaccines and immune stimulants. Researchers gave nine monkeys the combination of Ad26/MVA and GS-986. Then they stopped the antiretroviral drugs to see whether the different therapies would keep the SIV level in the monkey's blood under control.

The combo worked best at keeping SIV levels down, researchers found. All nine monkeys showed decreased levels, and the virus was undetectable in a third of them. "They rebounded initially, but after rebounding the virus was controlled," senior author Dan Barouch, M.D., Ph.D., director of the Center for Virology and Vaccine Research at the Beth Israel Deaconess Medical Center in Boston, told HealthDay. "They have remained undetectable up until the last time they were tested."

"Both of these components already are in clinical trials being conducted separately," Barouch added. "We hope to evaluate the combination in humans, and we plan to do further animal studies as well."

The study was funded by Janssen Vaccines & Prevention and Gilead Sciences, the manufacturers of Ad26/MVA and GS-986, respectively.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Recent Decline in Prescription Opioid Use Among U.S. Teens

Recent Decline in Prescription Opioid Use Among U.S. ...

Lifetime prevalence of use peaked in 1989, 2002, and remained stable until decline in 2013 to 2015

Treatment Seeking Low Among Teens With Eating Disorders

Treatment Seeking Low Among Teens With Eating Disorders

Those with counter-stereotypic presentation even less likely to seek treatment

Optical Clearing Agent Ups No. of Laser Passes in Tattoo Removal

Optical Clearing Agent Ups No. of Laser Passes ...

Findings based on number of laser passes during a five-minute tattoo removal session

is free, fast, and customized just for you!

Already a member?

Sign In Now »